Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HY-0102 by Shanghai HyaMab Biotech for Metastatic Colorectal Cancer: Likelihood of Approval
HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Metastatic Colorectal Cancer. According to...
HY-0102 by Shanghai HyaMab Biotech for Solid Tumor: Likelihood of Approval
HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Solid Tumor. According to GlobalData,...
HY-0102 by Shanghai HyaMab Biotech for Head And Neck Cancer: Likelihood of Approval
HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Head And Neck Cancer. According...
HY-0102 by Shanghai HyaMab Biotech for Liver Cancer: Likelihood of Approval
HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Liver Cancer. According to GlobalData,...
HY-0102 by Shanghai HyaMab Biotech for Lung Cancer: Likelihood of Approval
HY-0102 is under clinical development by Shanghai HyaMab Biotech and currently in Phase I for Lung Cancer. According to GlobalData,...